Targeting HER2 in ovarian and uterine cancers: Challenges and future directions

摘要: Targeting the human epidermal growth factor receptor 2 (HER2) has yielded major advances in breast cancer treatment. Accordingly, it generated interest targeting HER2 to treat gynecologic malignancies. Multiple studies have evaluated rates of overexpression and/or amplification ovarian and uterine cancers. also been studied as a prognostic but resulting data contradictory. Moreover, clinical trials HER2-directed therapies, including trastuzumab, pertuzumab, lapatinib cancers largely disappointing. Current research on malignancies focused identifying mechanisms resistance looking further into how signaling differs from cancer. In this review, we highlight existing carcinomas, many dating back more than decade, discuss future directions pursuing potential target these diseases.